Literature DB >> 11439344

Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.

P Giannakakou1, R Robey, T Fojo, M V Blagosklonny.   

Abstract

Paclitaxel (PTX), a microtubule-active agent, blocks cell proliferation by inhibiting mitotic progression leading to mitotic and postmitotic arrest and cell death. Here we demonstrate for the first time that very low concentrations of PTX (3-6 nM) can completely inhibit cell proliferation without arresting cells at mitosis. At these low concentrations that are insufficient to inhibit mitotic progression, PTX induced both p53 and p21 causing G1 and G2 arrest in A549. In contrast, low PTX concentrations failed to induce G1 and G2 arrest in A549/E6 cells, that do not express p53. Furthermore, we observed that the levels of p53 and p21 induced by adriamycin and by low concentrations of PTX in A549 cells were comparable. This observation led us to conclude that low concentrations of PTX can induce p53 and p21 sufficiently to cause G1 and G2. Many other cell lines, including HCT116 cells, do not readily upregulate p53 in response to PTX, and therefore undergo exclusively mitotic and postmitotic arrest after PTX treatment. At low concentrations that do not cause mitotic arrest, PTX did not significantly inhibit proliferation of these cells. In HCT116 cells, loss of p53 (HCT/p53(-/-)) or p21 (HCT/p21(-/-)) affects both Bax and Bcl-2 expression. In cells lacking p53, levels of Bax and p21 were decreased. In cells lacking p21, levels of wt p53 were highly increased to compensate for the loss of p21. This in turn results in upregulation of Bax and downregulation of Bcl-2 resulting in an increase of the apoptotic Bax/Bcl2 ratio consistent with increased sensitivity of these cells to apoptotic stimuli. High levels of p53 and Bax/Bcl-2 ratio can also explain why loss of p21 is rarely found in human cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439344     DOI: 10.1038/sj.onc.1204487

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  52 in total

1.  Activation of p21-Dependent G1/G2 Arrest in the Absence of DNA Damage as an Antiapoptotic Response to Metabolic Stress.

Authors:  L Alexis Hoeferlin; Natalia V Oleinik; Natalia I Krupenko; Sergey A Krupenko
Journal:  Genes Cancer       Date:  2011-09

2.  Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms.

Authors:  Cathy Andorfer; Christopher M Acker; Yvonne Kress; Patrick R Hof; Karen Duff; Peter Davies
Journal:  J Neurosci       Date:  2005-06-01       Impact factor: 6.167

Review 3.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

4.  Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion.

Authors:  Iara F Kretzer; Durvanei A Maria; Raul C Maranhão
Journal:  Cell Oncol (Dordr)       Date:  2012-10-03       Impact factor: 6.730

5.  In-vivo antiproliferative activity of Morus latifolia leaf and bark extracts against Ehrlich's ascites carcinoma.

Authors:  Md Shihabul Islam; Chowdhury Arif Jahangir; Md Sifat Rahi; Md Mahmudul Hasan; Salek Ahmed Sajib; Kazi Md Faisal Hoque; Md Abu Reza
Journal:  Toxicol Res       Date:  2019-11-21

6.  Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.

Authors:  M Orth; K Unger; U Schoetz; C Belka; K Lauber
Journal:  Oncogene       Date:  2017-09-04       Impact factor: 9.867

7.  In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer.

Authors:  Martin Pölcher; Christian Rudlowski; Nicolaus Friedrichs; Marieke Mielich; Tobias Höller; Mathias Wolfgarten; Kirsten Kübler; Reinhard Büttner; Walther Kuhn; Michael Braun
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

8.  p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell.

Authors:  Junxia Wei; Jiang Zhao; Min Long; Yuan Han; Xi Wang; Fang Lin; Jihong Ren; Ting He; Huizhong Zhang
Journal:  BMC Cancer       Date:  2010-11-19       Impact factor: 4.430

9.  Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies.

Authors:  Simeon K Adesina; Alesia Holly; Gabriela Kramer-Marek; Jacek Capala; Emmanuel O Akala
Journal:  J Pharm Sci       Date:  2014-06-24       Impact factor: 3.534

10.  SPR064, a pro-drug of paclitaxel, has anti-tumorigenic effects in endometrial cancer cell lines and mouse models.

Authors:  Xiaoling Zhao; Weimin Kong; Katherine Tucker; Allison Staley; Yali Fan; Wenchuan Sun; Yajie Yin; Yu Huang; Ziwei Fang; Jiandong Wang; Somdutta Sen; Sundeep Dugar; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2020-08-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.